Healthcare Regulation (HIPAA)

With a new $15M, Ours Privacy is tackling healthcare's biggest marketing challenge: growing without violating patient privacy in a strict regulatory world.

A new "healthcare intelligence flywheel" promises to predict illness using AI and wearables. But can Pomdoctor's ambitious model navigate the realities of data privacy and market competition?

PulsePoint's second consecutive 'Programmatic Platform of the Year' award highlights a major shift. How is its tech bridging the gap between doctors and patients?

Vasion and Imprivata are tackling the print security blind spot with an integration that extends digital identity to the printer, a critical move for PHI.

Wellgistics Health rebrands as DataMeds AI, promising a new era of patient empowerment. But can its ambitious AI and blockchain vision overcome a history of financial distress?

A strategic alliance between Harmony Healthcare IT and Carahsoft promises to simplify complex data archiving and compliance for government health agencies.

Alberta is launching a controversial private healthcare option, promising efficiency. Critics warn it's a two-tier system that will let the rich jump the queue.

As healthcare rushes to adopt AI, a young company's award win spotlights the critical, multi-billion dollar race to ensure innovation doesn't outpace safety.

Life science labs are eagerly exploring AI, but new data reveals a major roadblock: a fragmented digital landscape that keeps true innovation just out of reach.

R1's new Phare OS intelligence engine promises to upend the slow, costly cycle of medical claims. Can real-time adjudication finally fix a broken system?

New detachable sensor leads from Monnit allow for instant recertification, eliminating costly downtime in pharma and healthcare while ensuring data integrity.

A new patent gives CervoMed a long runway for its dementia drug, but can this IP victory secure the massive funding needed to cross the finish line?

With a fresh $50M, Enhanced Group is selling a future of medically-guided peak performance. But can its controversial Games and peptide platform survive regulatory scrutiny?

At BIO 2026, Transpire Bio isn't just presenting; it's pitching a new paradigm for medicine, using inhalation to tackle everything from diabetes to cancer.

An Arkansas lab's $30 million settlement with the DOJ offers a rare look into 'lean lab' models and the fine line between business and patient care.

GSK and Spero Therapeutics have won FDA approval for Utebzi, the first oral carbapenem for complex UTIs, a move that could slash healthcare costs.

A new network aims to speed up clinical trials by recruiting patients from med spas and longevity clinics. Is this the future of medicine or a risky new frontier?

With 180-day exclusivity, Lupin's generic hypertension drug launch is set to disrupt a $53M market, highlighting a masterclass in pharmaceutical strategy.

With a novel FDA clearance for its at-home UVB device, Solius Labs isn't just launching a product; it's creating a new market for personalized medicine.

A new report reveals which cannabis brands dominate AI search, just as federal rescheduling creates chaos and opportunity. But with AI often refusing to answer, who wins?